| Analysis | Metabolite Name | Measured Value | Units | Group | TIMEPOINT |
|---|---|---|---|---|---|
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.2231 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.4337 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.4728 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.5587 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.5644 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.5796 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.5802 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6032 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6264 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6303 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6374 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6400 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6444 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6755 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6838 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6884 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.6923 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7081 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7150 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7254 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7305 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7344 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7383 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7414 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7709 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7773 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7872 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.7875 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.8090 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.8091 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.8232 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.8328 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.8389 | scaled units | High-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.8582 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9014 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9058 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9124 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9423 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9465 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9582 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9672 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9725 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9828 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9843 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 0.9908 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.0092 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.0172 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.0255 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.0338 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.0349 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.0420 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.0428 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.0851 | scaled units | High-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.0917 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.1012 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.1122 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.1452 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.1483 | scaled units | High-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.1501 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.1553 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.1627 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.1928 | scaled units | Placebo | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.2191 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.2345 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.2758 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.2899 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.2932 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.3094 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.3318 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.3535 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.3629 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.3786 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.4273 | scaled units | Low-Dose | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.4351 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.4646 | scaled units | High-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.5062 | scaled units | Low-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.5531 | scaled units | Low-Dose | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.6827 | scaled units | Placebo | +47HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.7587 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.9254 | scaled units | High-Dose | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 1.9556 | scaled units | Low-Dose | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 2.1329 | scaled units | Placebo | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 2.3772 | scaled units | Low-Dose | +4HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 2.4026 | scaled units | High-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 2.6313 | scaled units | Low-Dose | -0.5HR |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 2.6346 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 2.6932 | scaled units | Placebo | +71HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 3.0118 | scaled units | Placebo | BASELINE |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 3.0390 | scaled units | Placebo | +23HR POST INFUSION |
| Reversed phase NEGATIVE ION MODE | 4-hydroxyphenylacetate | 3.0392 | scaled units | Placebo | BASELINE |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|